240 related articles for article (PubMed ID: 37011399)
41. On variants and vaccines: The effectiveness of Covid-19 monoclonal antibody therapy during two distinct periods in the pandemic.
Srinivasan V; Weinstein SE; Bhimani A; Clemons NC; Dinolfo M; Shin CS; Grier J; Lopez A; Braggs J; Boucher J; Batiste QN; Garner OB; Yang S; Vijayan T
PLoS One; 2022; 17(12):e0278394. PubMed ID: 36454767
[TBL] [Abstract][Full Text] [Related]
42. Real World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients.
Wynia MK; Beaty LE; Bennett TD; Carlson NE; Davis CB; Kwan BM; Mayer DA; Ong TC; Russell S; Steele J; Stocker HR; Wogu AF; Zane RD; Sokol RJ; Ginde AA
medRxiv; 2022 Jan; ():. PubMed ID: 35043117
[TBL] [Abstract][Full Text] [Related]
43. Outcome of COVID-19 in Kidney Transplant Recipients Through the SARS-CoV-2 Variants Eras: Role of Anti-SARS-CoV-2 Monoclonal Antibodies.
Papadimitriou-Olivgeris M; Cipriano A; Guggisberg N; Kroemer M; Tschopp J; Manuel O; Golshayan D
Transpl Int; 2022; 35():10721. PubMed ID: 36267693
[TBL] [Abstract][Full Text] [Related]
44. SARS-CoV-2 Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Kidney Transplant Recipients.
Wang AX; Busque S; Kuo J; Singh U; Röeltgen K; Pinsky BA; Chertow GM; Scandling JD; Lenihan CR
Kidney360; 2022 Jan; 3(1):133-143. PubMed ID: 35368573
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and Safety of Anti-SARS-CoV-2 Monoclonal Antibodies: An Updated Review.
Ravi G; Eerike M; Konda VR; Bisoi D; Raj GM; Priyadarshini R; Mali KR; Chaliserry LF
Monoclon Antib Immunodiagn Immunother; 2023 Apr; 42(2):77-94. PubMed ID: 37129306
[TBL] [Abstract][Full Text] [Related]
46. Antispike monoclonal antibodies for prevention and treatment of coronavirus disease-2019 in solid organ transplant recipients.
Yetmar ZA; Bhaimia E; Razonable RR
Curr Opin Organ Transplant; 2022 Aug; 27(4):269-276. PubMed ID: 36354253
[TBL] [Abstract][Full Text] [Related]
47. Dual Monoclonal Antibodies on Sars-Cov-2 Alpha and Delta Variants: Clinical and Virological Efficacy.
Ferré VM; Peiffer-Smadja N; Kramer L; Coppée R; Kante A; Debarge M; Choquet C; Saint Joannis T; Bouzid D; Messika J; Le Grand J; Thy M; Kernéis S; Descamps D; Visseaux B; Ghosn J
Microbiol Spectr; 2022 Oct; 10(5):e0215222. PubMed ID: 36125289
[TBL] [Abstract][Full Text] [Related]
48. Initial Experience With SARS-CoV-2-Neutralizing Monoclonal Antibodies in Kidney or Combined Kidney-Pancreas Transplant Recipients.
Bachmann F; Budde K; Suttorp N; Lingscheid T; Stegemann MS; Osmanodja B; Schrezenmeier E; Duettmann W; Weber U; Naik M; Lehner LJ; Kahl A; Duerr M; Eckardt KU; Waiser J; Choi M; Halleck F
Transpl Int; 2022; 35():10109. PubMed ID: 35431640
[No Abstract] [Full Text] [Related]
49. Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents.
Wolf J; Abzug MJ; Anosike BI; Vora SB; Waghmare A; Sue PK; Olivero RM; Oliveira CR; James SH; Morton TH; Maron GM; Young JL; Orscheln RC; Schwenk HT; Bio LL; Willis ZI; Lloyd EC; Hersh AL; Huskins CW; Soma VL; Ratner AJ; Hayes M; Downes K; Chiotos K; Grapentine SP; Wattier RL; Lamb GS; Zachariah P; Nakamura MM
J Pediatric Infect Dis Soc; 2022 May; 11(5):177-185. PubMed ID: 35107571
[TBL] [Abstract][Full Text] [Related]
50. Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection.
Bavaro DF; Diella L; Solimando AG; Cicco S; Buonamico E; Stasi C; Ciannarella M; Marrone M; Carpagnano F; Resta O; Carpagnano GE; Palmieri VO; Vacca A; Dell'Aera M; Dell'Erba A; Migliore G; Aricò M; Saracino A
Pathog Glob Health; 2022 Jul; 116(5):297-304. PubMed ID: 35138229
[TBL] [Abstract][Full Text] [Related]
51. Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
O'Horo J; Challener DW; Anderson RJ; Arndt RF; Ausman SE; Hall ST; Heyliger A; Kennedy BD; Sweeten PW; Ganesh R; Razonable RR
Mayo Clin Proc; 2022 May; 97(5):943-950. PubMed ID: 35512884
[TBL] [Abstract][Full Text] [Related]
52. Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4/BA.5.
Molina KC; Kennerley V; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Aggarwal NR; Ginde AA
Int J Infect Dis; 2023 Jul; 132():34-39. PubMed ID: 37072054
[TBL] [Abstract][Full Text] [Related]
53. Effectiveness of Casirivimab-Imdevimab Monoclonal Antibody Treatment Among High-Risk Patients With Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617.2 (Delta Variant) Infection.
Al-Obaidi MM; Gungor AB; Nematollahi S; Zangeneh TT; Bedrick EJ; Johnson KM; Low-Adegbija NE; Alam R; Rangan P; William Heise C; Ariyamuthu VK; Shetty A; Qannus AA; Murugapandian S; Ayvaci MMS; Anand PM; Tanriover B
Open Forum Infect Dis; 2022 Jul; 9(7):ofac186. PubMed ID: 35791354
[TBL] [Abstract][Full Text] [Related]
54. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
[TBL] [Abstract][Full Text] [Related]
55. Clinical outcomes of monoclonal antibody therapy during a COVID-19 outbreak in a skilled nursing facility-Arizona, 2021.
Dale AP; Hudson MJ; Armenta D; Friebus H; Ellingson KD; Davis K; Cullen T; Brady S; Komatsu KK; Stone ND; Uyeki TM; Slifka KJ; Pérez-Vélez CM; Keaton AA
J Am Geriatr Soc; 2022 Apr; 70(4):960-967. PubMed ID: 35141874
[TBL] [Abstract][Full Text] [Related]
56. Calcitonin Gene-Related Peptide Monoclonal Antibodies and Risk of SARS-CoV-2 Infection and Severe COVID-19 Outcomes Among Veterans With Migraine Disorder.
Wang K; Fenton BT; Deng Y; Anthony SE; Dao VX; Schindler E; Lipton RB; Guirguis A; Skanderson M; Seng EK; Sico JJ
JAMA Netw Open; 2023 Jul; 6(7):e2326371. PubMed ID: 37523183
[TBL] [Abstract][Full Text] [Related]
57. Anti-SARS-CoV-2 monoclonal antibodies for the treatment of mild-to-moderate COVID-19 in multiple sclerosis: A retrospective cohort study.
Jin H; Geiger C; Jessop N; Pedotti R; Raposo C; Whitley L; Brown JS; Muros-Le Rouzic E
Mult Scler Relat Disord; 2023 Nov; 79():104943. PubMed ID: 37716211
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of severe acute respiratory syndrome coronavirus 2 monoclonal antibodies in high-risk solid organ transplant recipients across three major coronavirus disease 2019 variant waves.
Zeitler K; Piccicacco N; O'Neal M; Montero J; Myers A; Strebig D; Nestler S; Anger LB; Kim K
Transpl Infect Dis; 2023 Aug; 25(4):e14095. PubMed ID: 37378536
[TBL] [Abstract][Full Text] [Related]
59. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
60. Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge.
Bierle DM; Ganesh R; Razonable RR
J Clin Virol; 2021 Dec; 145():105026. PubMed ID: 34775142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
